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Abstract  
Objectives: After 20 years of data collection, pregnancy registers have informed prescribing 
practice. Various populations show trends for a reduction in valproate prescribing, which is 
associated with an increased risk of anatomical teratogenesis and neurodevelopmental 
effects in those exposed in utero.  Our aim was to determine if any shifts in prescribing 
trends have occurred in the UK and Ireland Epilepsy and Pregnancy Register cohort, and to 
assess if there had been any change in the overall major congenital malformation (MCM) 
rate over time. 
Methods: The UK and Ireland Epilepsy and Pregnancy Register, a prospective, 
observational, registration and follow up study established in 1996, was used to determine 
the changes in antiepileptic drugs (AEDs) utilised during pregnancy and the MCM rate 
between 1996 and 2016. Linear regression analysis was used to assess changes in AED 
utilisation, and Poisson regression was used for the analysis of trends in the MCM rates.  
Results: Outcome data for 9247 pregnancies showed a stable percentage of monotherapy to 
polytherapy prescribing habits over time. After Bonferroni correction, statistically significant 
(P<0.003) changes were found in monotherapy prescribing with increases in lamotrigine and 
levetiracetam and decreases in valproate and carbamazepine use. Between 1996 and 2016 
the total MCM appeared to show 2.1% reduction in MCM rate per year (Incidence risk ratio 
0.979 [95% confidence intervals 0.956-1.002] but Poisson regression analysis showed that 
this was not statistically significant P =0.08).  
Conclusion: Significant changes are seen in the prescribing habits in this cohort over 20 
years, but a statistically significant change in the MCM rate was not detected. This work 
should be replicated on a larger scale to determine if significant changes are occurring in the 
MCM rate, which would allow a robust economic estimate of the benefits of improvements in 
prescribing practice and the personal effect of such changes.  
 
 
 
 
 
 
  
 
Introduction 
For two decades various epilepsy and pregnancy registers have prospectively gathered data 
on pregnancy outcomes in women with epilepsy (WWE) exposed to antiepileptic drugs 
(AEDs) (1). The consensus from these various registry studies is that, in order to reduce the 
risk of major congenital malformation (MCM), WWE should take low dose AEDs in 
monotherapy and preferably avoid valproate whenever possible (2,3,4). Prescribing trends 
reported from different regions indicate a change in prescribing practice (5,6,7,8).  
In general, trends in prescribing in WWE have shown that valproate and carbamazepine use 
has declined. In their place lamotrigine and levetiracetam have become the two most 
commonly prescribed AEDs (6, 7, 8). These changes could be predicted due to concerns of 
structural teratogenicity as well as neurocognitive dysfunction with valproate and lower 
tolerability with carbamazepine. Although of importance in some regions, the prescribing of 
valproate has reportedly increased for non-epilepsy indications (9).  
The aim of this study was to determine the extent of change in prescribing practice within the 
UK and Ireland Epilepsy and Pregnancy Register (UKIEPR). We also sought to determine if 
these changes impacted on the foetal MCM rate in this population.  This has not been well 
studied to date. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Methods 
The UKIEPR is a prospective, observational, registration and follow up study that was set up 
in 1996 to determine the relative safety of AEDs taken in pregnancy.  Methodological details 
have been published previously (2). Herein we report the congenital malformation outcomes 
of all pregnancies reported to the UKIEPR from 1996 through to August 2016.   
Eligible cases were women with epilepsy taking any AED who were referred to the UKIEPR 
before the outcome of the pregnancy was known. Cases are referred by neurologists, 
epilepsy specialist nurses, obstetricians, midwives and by self-registering patients. Cases 
that are referred after an antenatal diagnosis of a probable or definite MCM are excluded. 
The main outcome measure is MCM rate defined as an abnormality of an essential 
embryonic structure requiring significant treatment, being present at birth or discovered in 
the first six weeks of life. Pregnancy losses where the outcome could not be determined 
were excluded, if a pregnancy loss occurred but a MCM was identified, these cases were 
included in the analysis. Outcome data are collected 3 months post-delivery by a 
questionnaire sent to the patient’s general practitioner.  
 
Statistical Analysis 
Analyses of changing AED prescription trends over time have been carried out over the time 
course of the study from December 1996 through to 31st August 2016.  Data from 1996 until 
December 2000 due to limitations in the data retrieval system is presented as cumulative 
data, contained in the data for the year 2000. For the rest of the time course of the study the 
data were recorded for individual years. The main analysis of the MCM rate data was by 
Poisson regression. The incidence risk ratio (IRR) is the measure most suitable for 
displaying these trends. A value of 1.000 represents no change in MCM risk from one year 
to the next.  A value of 1.010 represents a 1% increase in year on year risk and 0.990 a 1% 
decrease. Trends in individual monotherapy and overall polytherapy prescribing were 
derived from data expressed as a percentage of all patients prescribed an AED, who were 
analysed by simple regression analysis.  
Exact binomial 95% confidence intervals for proportions were calculated.  SPSS 
Version.23.0 (IBM Corp., Armonk, NY) was used for the simple linear regression and 
Poisson regression analyses. Statistical significance level was set with a Bonferroni 
correction for 15 analyses at P<0.003 (=0.05/15). 
 
  
 
Results 
Between December 1996 and 31st August 2016, complete outcome data were available for 
9247 pregnancies, of which 6785 (73.4%) were on monotherapy, 1858 (20.1%) were on 
polytherapy regimens and 604 (6.5%) were not on AEDs. Of the 8643 exposed to AEDs, 
8181 pregnancies resulted in a live birth, of which 305 resulted in an infant with a MCM.  
Among those exposed to AED therapy, where the pregnancy resulted in foetal loss, there 
were 40 MCMs.  Further details can be found in Supplementary table 1.  
Of all cases treated with AEDs, the mean number who annually were treated with 
polytherapy is 17.5% (range 9-29%). Simple regression carried out on the polytherapy 
annual trend, did not identify any significant overall change in the polytherapy prescribing 
rate (regression slope -0.14, SE 0.22, P=0.53).  
 
Figure 1 demonstrates the observed trends in prescribing changes, which clearly show the 
significant increase in the prescribing of lamotrigine and levetiracetam and the significant 
reduction in prescribing of valproate and carbamazepine. Based on a simple regression 
analysis the trend for valproate (regression slope -1.37, SE 1.00), [indicating that there has 
been a reduction of valproate registrations by 1.37% per year during the period of the study] 
carbamazepine (regression slope -1.19, SE 0.10) lamotrigine (regression slope 1.15, SE 
0.22), and levetiracetam (regression slope 1.71, SE 0.11) all showed statistically significant 
changes over the time course of the study (P<0.003). The miscellaneous group had a 
regression slope of -0.15, SE 0.05 (P =0.007) which was not significant after adjustment for 
multiple comparisons. The linear plots of these trends are presented in Figure 2 (See 
supplementary file 2).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Treatment Incidence risk ratio 
(IRR) 
95% Confidence intervals P Value 
Lower Upper 
Lamotrigine 0.984 0.927 1.044 0.60 
Carbamazepine 1.057 0.999 1.117 0.06 
Levetiracetam 1.255 0.961 1.640 0.10 
Sodium Valproate 0.976 0.923 1.033 0.40 
Miscellaneous 
monotherapy 
1.034 0.942 1.134 0.49 
No AED group 0.994 0.884 1.119 0.92 
Polytherapy 0.986 0.945 1.028 0.51 
Total (Monotherapy 
and Polytherapy) 
0.979 0.956 1.002 0.08 
 
 
Table 1: Results from Poisson Regression analysis of annualised MCM rates.  
 
Table 1 shows the results of a Poisson regression analysis carried out with MCM as the 
dependent variable, and year of study as a covariate. The analysis showed individual 
monotherapy drug MCM rates and the total MCM rate (monotherapy and polytherapy 
combined) did not change significantly over the course of the study. However the incidence 
risk ratio for total MCM rate does indicate a non-significant 2.1% reduction in the MCM rate 
per year. The trend for the MCM rate with lamotrigine, valproate, no AED group, 
polytherapy, levetiracetam, miscellaneous, and carbamazepine were all non-significant.   
 
  
 
Discussion 
In this study we evaluated the AED reporting patterns to the UKIEPR and have 
demonstrated that there have been statistically significant changes in the preferred agents 
used in monotherapy prescribing to WWE in the UK and Ireland. The overall amount of 
polytherapy prescribed relative to monotherapy has not significantly changed, likely 
indicating that the severity of the cases referred to the UKIEPR over time has not changed. 
In keeping with other registry and population based prescribing studies (5,6,7,8) our key 
finding is the significant change in the prescribing habits in monotherapy, favouring the less 
teratogenic drugs and those with a safer neurodevelopmental profile. The main factors which 
would explain these observed changes in prescribing practice, would include the reporting 
and dissemination of results from the various epilepsy and pregnancy registers, and in 2002 
it was reported from retrospectively collected information that valproate exposure in utero 
resulted in reduced verbal Intelligence Quotient (10). In 2003 the Committee on Safety of 
Medicines (11) advised caution with valproate. More recently publications from the European 
Medicines Agency (EMA) (12), and the International League Against Epilepsy (ILAE) (13) 
have reiterating the importance of considering the safety of valproate use in women of 
childbearing age, with respect to risks of teratogenicity and neurodevelopmental 
abnormalities. 
An alternative explanation for reduced numbers of valproate cases being registered is that 
patients and practitioners are better informed of the risks of valproate and consequently 
decline to register for the study, giving the impression of a reducing rate of valproate 
prescribing. However our findings are similar to a UK primary care prescribing database, 
suggesting that this is an accurate observation of reduced valproate prescribing (6). The 
reduction in the use of carbamazepine cannot be explained simply in terms of its 
teratogenicity but may be related to issues regarding poor tolerability due to its enzyme 
inducing effects (2, 3, 4). 
Despite only provisional data being available in a small number of prospectively followed 
children, detrimental cognitive effects have not been consistently found with levetiracetam 
and lamotrigine in children studied to the age of 6 (14). Despite these being provisional data, 
it is possibly a factor in women favouring these medication options. 
If the increasing trends for MCM rate with levetiracetam and carbamazepine were 
subsequently found to be true, these would require explanation. Levetiracetam was 
introduced during the course of this study, and it took time to determine an accurate MCM 
rate, so giving the impression of an increasing MCM rate, albeit to its present low level.  
Regarding carbamazepine, the increasing MCM rate is perhaps of more interest. Patients 
  
 
taking carbamazepine at the start of this study differ phenotypically from those women 
registering now. At the outset of the register, carbamazepine was a first line treatment for 
focal epilepsy, now preference is given to lamotrigine or levetiracetam, thus women who are 
using carbamazepine now are potentially older, have more refractory epilepsy, and could 
potentially be on a higher dose of carbamazepine than women who first enrolled. This does 
require further work to determine what changes may be occurring over time in this 
population. The trend towards an increasing MCM rate within the miscellaneous group may 
reflect topiramate use which is known to be an intermediate risk monotherapy agent (15).  
 Although an overall reduction in MCM was observed during the study period, our Poisson 
regression analyses failed to detect it as statistically significant. Future work might allow for 
collaboration between the different pregnancy registries to reanalyse this question, as it is 
expected that data provided on a larger scale would show a statistically significant change in 
the MCM rate given the reduction in teratogenic drug use. The Australian Register of AEDs 
in Pregnancy (8) also found a downward trend in MCM rate with time but this failed to reach 
statistical significance.  The authors attributed the trend to reduced use of valproate and a 
reduced dosage of valproate. 
The strength of these data are the prospective nature of collection over a long time frame, 
resulting in the one of the largest cohorts of female epilepsy specific prescribing data 
reported to date. In terms of limitations of this present work, it is possible that prescribing 
trends are occurring within the population of WWE which are not reflected in this current 
work due to referral bias.  In the initial stages the register received about 30% referrals from 
the total eligible population of WWE, but this has reduced to 10-15% in recent years. The 
background rate of MCM may be falling due to other improvements in health, which could 
have resulted in a trend for reduced MCM. A further limitation is the fact that the dose of the 
AEDs was not analysed, and will be the subject of a future analysis. Data was analysed as 
annual aggregates and thus important co-variates in the assessment, such as smoking 
status, background change in MCM, folate status and history of malformation could not be 
included in the analysis. The particular prescribing changes occurring internally within the 
polytherapy group need to be re-evaluated in terms of dose and type of combinations used.  
 In conclusion, this study has shown a change in prescribing habit in the UKIEPR 
demonstrating a preference towards using AEDs with reduced potential for MCM and 
neurodevelopmental delay. Although being the largest epilepsy registry study to date to 
attempt to analyse the MCM rate over time, we have not found a statistically significant 
change.   
 
  
 
Figure 1 
 
The annual changes in individual AED monotherapy and AED polytherapy registrations to 
the UK and Ireland epilepsy and pregnancy register.  
 
Annual changes in individual monotherapy AED and polytherapy registrations
Miscellaneous
  
 
  
 
Supplementary file 2 
 
Linear plots of individual AED monotherapy and AED polytherapy annual registrations.  
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